Foamix Pharmaceuticals Ltd. Культура компании

Mr. Ilan Hadar, MBA, has been the Chief Financial Officer of Foamix Pharmaceuticals Ltd., since February 2014 and its Country Manager since July 9, 2017. Mr. Hadar is responsible for corporate financial reporting, audit, treasury, tax and internal controls. Prior to joining Foamix, he held several chief financial officer positions and executive financial positions with several Hi-Tech (like HP and BAE Systems) and Pharmaceutical companies in Israel. He has extensive operational and financial reporting experience with multinational companies, working with companies located in the US and the UK. Previously, Mr. Hadar served as the head of accounting and reporting department in HP Indigo. He was responsible for corporate reporting and control, internal and external audit. He served as the Chief Financial Officer at Mango DSP Ltd. since July 1998. He served as the Chief Financial Officer at Marnetics Broadband Tech. Ltd., where he managed the financial activities of several startup companies on behalf of the Jerusalem based incubator HiTEC. He served as the Chief Financial Officer of Globus Group Television Studios. Mr. Hadar earned his bachelor's degree in business and economics and his Master's in Business Administration from the Hebrew University in Jerusalem.

Mr. Meir Eini serves as Chief Executive Officer of FlexiProbe Ltd. Mr. Eini is a Co-Founder of Foamix Pharmaceuticals Ltd. and has been its Innovation Advisor since June 29, 2017. He served as Chief Innovation Officer at Foamix Pharmaceuticals Ltd. since 2014. He served as the Chief Operations Officer at Foamix Pharmaceuticals Ltd. since January 2003. He co-invented the Foamix Oil Gel and Foam technologies. He is an experienced entrepreneur and has many years of experience in the initiation, setting-up and running of technology-oriented businesses including the set-up and operation of a US subsidiary of Sharnoa LTD (industrial computers and controls). He founded and oversees management of Clilco (innovative consumer healthcare), Thixo (oilgel food technology) and Flexiprobe (medical device for women's health). Mr. Eini served as the Chairman of Foamix Pharmaceuticals Ltd. from January 2003 to May 16, 2016. Mr. Eini is the inventor or co-inventor of 25 patents in the fields of healthcare, food and medical equipment.

Mr. Alvin D. Howard has been Vice President of Regulatory Affairs - Foamix Pharmaceuticals Inc. at Foamix Pharmaceuticals Ltd. since April 2014. Mr. Howard has over 30 years of industry experience. He served as Senior Vice President of Regulatory Affairs at Warner Chilcott plc and Warner Chilcott Limited/Warner Chilcott Plc. (Formerly Galen Holdings Plc.) from 2005 to 2013. Mr. Howard was responsible for the registration of products and for managing Warner Chilcott Plc.'s relationships with the FDA, Health Canada and other agencies regulating the sale of pharmaceutical products. He served as the Vice President of Regulatory Affairs of Warner Chilcott Limited and Warner Chilcott Corporation since joining in February 5, 2001. He served various positions at Solvay Pharmaceuticals from 1990 to 1998. He served as the Senior Vice President of Regulatory Affairs of Warner Chilcott Holdings Company III, Limited and Warner Chilcott Corporation. Prior to joining Galen, he served as Vice President of Worldwide Regulatory Affairs of Roberts Pharmaceuticals from 1998 to 2000. Mr. Howard holds a B.Sc. in chemistry from Stillman College, Tuscaloosa, Alabama.

Mr. David Schuz has been an Executive Vice President of Intellectual Property at Foamix Pharmaceuticals Ltd since 2010. Mr. Schuz served as Senior Vice President, Intellectual Property of Foamix Ltd. since July 2006. Mr. Schuz joined Foamix from Bio-Technology General (Israel) Ltd. where he served as Vice President of Legal. He also served at various times as Acting General Counsel, Associate General Counsel, Senior Director and Head of IP Worldwide of Savient Pharmaceuticals Inc. From 1984 to 1999, Mr. Schuz held legal and intellectual property positions at S. Horovitz & Co., Advocates and Patent Attorneys, at Dr. Reinhold Cohn and Partners, Patent Attorneys, as well as at Raymond Saul & Co., Solicitors. He also lectured on patent issues at the Faculty of Law at Bar Ilan University, from 1996 to 2001. He acquired his legal and intellectual property education at LSE, University of London, QMW, University of London and the University of Trent, Nottingham, UK. He also holds an M. Phil. Degree in Biochemistry and a Diploma of Pharmacology from the University of Cambridge.

Dr. Iain A. Stuart, Ph.D., has been Senior Vice President of Research & Development at Foamix Pharmaceuticals Ltd. since August 2017. Dr. Stuart served as Vice President of Clinical Development at Foamix Pharmaceuticals Ltd. from October 2016 to August 2017. Dr. Stuart served as Vice President of Medical Strategy & Scientific Affairs of LEO Pharma Inc. since March 2016. He was responsible for building and managing the medical strategy and scientific affairs function for the U.S. Region and the development of strategy, policies and programs in the areas of Quality, Pharmacovigilance, Drug Safety, Regulatory Affairs, Scientific Affairs and Medical Information, including publications and due diligence activities. Dr. Stuart joined LEO U.S. in March 2013 as Director, Clinical Operations - The Americas. In April of 2014, he was promoted to the position of Executive Director, Medical Strategy & Scientific Affairs. Prior to his position at LEO U.S., he joined LEO Pharma A/S in 2008 as Director of Preclinical Development at LEO Pharma in Ballerup. In 2010, he advanced into the positions of Vice President, LEO Project Management and Vice President and Managing Director, Peplin Operations USA, Inc. Dr. Stuart has over 18 years of clinical development scientific affairs experience in multiple therapeutic classes with the last 8 years being focused exclusively in dermatology. Dr. Stuart was responsible for the shut down and transfer for the PEP005 project (now Picato??) from Peplin to LEO Pharma. He also served as a member of the Global Management Team while he was in Denmark. Prior to joining LEO Pharma A/S, Dr. Stuart worked from 2001 to 2008 at Cyclacel Pharmaceuticals based out of Berkeley Heights, NJ and Dundee, UK as a Preclinical Project Manager and Head of ADME and prior to Cyclacel, he was at Charles River (formerly Inveresk Research) in Edinburgh, UK as a Senior Study Director. Dr. Stuart holds a BSc. in Chemistry as well as a Ph.D. from Glasgow Caledonian University and completed his post-doctorate research fellowship at the University of Strathclyde.

Dr. Mitchell Shirvan, Ph.D., M.B.A., has been Senior Vice President of Research and Development at Foamix Pharmaceuticals Ltd since March 2013 and served as its R&D Director until March 2013. Dr. Shirvan served as the Chief Executive Officer of Macrocure Limited. Prior to this he was with Teva Pharmaceutical Industries; for 8 years in Strategic Business Planning and for 8 years head of anti-epileptic drug development and a late stage product for Alzheimer's disease. Dr. Shirvan holds a Ph.D. in microbiology from The Hebrew University of Jerusalem and an MBA from the University of Bradford.